Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ex Vivo Perfusion of Gene-Edited Porcine Livers in Patients With Severe Hepatic Failure
NCT07519005Phase 1Active, not recruiting
- Sponsor
- Xijing Hospital
- Start
- Jan 2026
- Primary completion
- Feb 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in liver failure, sponsored by Xijing Hospital. Primary endpoint: Change in liver function parameters from baseline up to 14 days. Started Jan 2026; status: active, not recruiting.
02
Conditions
liver failure
Beyond the preview
Go deeper on NCT07519005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07519005.